Laboratoire GlycoMEV UR 4358, Université de Rouen Normandie, SFR Normandie Végétal FED 4277, Innovation Chimie Carnot, 76000 Rouen, France.
MGX-Montpellier GenomiX, Univ. Montpellier, CNRS, INSERM, 34094 Montpellier, France.
Mar Drugs. 2024 Jul 30;22(8):353. doi: 10.3390/md22080353.
The production of biologics in mammalian cells is hindered by some limitations including high production costs, prompting the exploration of other alternative expression systems that are cheaper and sustainable like microalgae. Successful productions of biologics such as monoclonal antibodies have already been demonstrated in the diatom ; however, limited production yields still remain compared to mammalian cells. Therefore, efforts are needed to make this microalga more competitive as a cell biofactory. Among the seventeen reported accessions of , ten have been mainly studied so far. Among them, some have already been used to produce high-value-added molecules such as biologics. The use of "omics" is increasingly being described as useful for the improvement of both upstream and downstream steps in bioprocesses using mammalian cells. Therefore, in this context, we performed an RNA-Seq analysis of the ten most used accessions (Pt1 to Pt10) and deciphered the differential gene expression in pathways that could affect bioproduction of biologics in . Our results highlighted the benefits of certain accessions such as Pt9 or Pt4 for the production of biologics. Indeed, these accessions seem to be more advantageous. Moreover, these results contribute to a better understanding of the molecular and cellular biology of .
真核细胞生物制药生产受到一些限制，包括高生产成本，这促使人们探索更便宜、更可持续的替代表达系统，如微藻。已经在硅藻中成功生产出生物制药，如单克隆抗体，但与哺乳动物细胞相比，产量仍然有限。因此，需要努力使这种微藻更具竞争力，成为细胞生物工厂。在已报道的 17 个 中，迄今为止主要研究了其中的 10 个。其中一些已被用于生产生物制药等高附加值分子。“组学”的使用越来越多地被描述为在使用哺乳动物细胞的生物工艺的上下游步骤的改进中是有用的。因此，在这种情况下，我们对使用最多的 10 个 （Pt1 到 Pt10）进行了 RNA-Seq 分析，并破译了可能影响生物制药生物生产的途径中的差异基因表达。我们的结果强调了某些 （如 Pt9 或 Pt4）在生产生物制药方面的优势。事实上，这些品系似乎更有利。此外，这些结果有助于更好地理解 的分子和细胞生物学。
